

Supporting Information

Nanotherapeutic macrophage-based immunotherapy for peritoneal carcinomatosis of lung cancer

Yonghui Wang ^{1, 2, 3}, Binfan Chen ^{1, 2}, Zhidi He ^{1, 2, 4}, Bin Tu ^{1, 2, 3}, Pengfei Zhao ¹, Huiyuan Wang ¹, Akmal Asrorov ^{1, 5}, Bahtiyor Muhitdinov ^{1, 5}, Jizong Jiang ^{1, 6}, Yongzhuo Huang ^{1, 2, 3, 7*}

Table S1: Drug encapsulation efficacy and drug-loading capacity of the celastrol NPs.

	Encapsulation efficacy (%)	Drug-loading capacity (%)
The NPs	81.7 ± 1.2	6.6 ± 0.3

Table S2: Gene primers used for q-PCR

Gene	Forward primer	Reverse primer
Arg1	GAACACGGCAGTGGCTTTAAC	TGCTTAGCTCTGTCTGCTTTGC
CD206	TCTTTGCCTTTCCCAGTCTCC	TGACACCCAGCGGAATTTC
IL-10	CAGGGATCTTAGCTAACGGAAA	GCTCAGTGAATAAATAGAATGGGAAC
IL-12p40	GCAACGTTGGAAAGGAAAGA	AAAGCCAACCAAGCAGAAGA
IL-12p35	ACTAGAGAGACTTCTCCACAACAAGAG	GCACAGGGTCATCATCAAAGAC
CD86	TTGTGTGTGTTCTGGAAACGGAG	AACTTAGAGGCTGTGTTGCTGGG
TNF- α	CCTGTAGCCACGTCGTAGC	AGCAATGACTCCAAAGTAGACC
F4/80	TGACTCACCTTGTGGTCCTAA	CTTCCCAGAATCCAGTCTTTCC
IL-1 β	GGACAAGCTGAGGAAGATGC	TCGTTATCCCATGTGTCGAA
IFN- γ	ATGAACGCTACACACTGCATC	CCATCCTTTTGCCAGTTCCTC
Gram B	CCACTCTCGACCCTACATGG	GGCCCCCAAAGTGACATTTATT
Ym1	CATGAGCAAGACTTGC GTGAC	GGTCCAAACTTCCATCCTCCA
Fizz1	CCCTGCTGGGATGACTGCTA	TGCAAGTATCTCCACTCTGGATCT
Actin	GGTCATCACTATTGGCAACG	ACGGATGTCAACGTCACACT




Figure S1 (A) HPLC chromatogram of celastrol. (B) Standard curve of celastrol. (C) Standard curve of Cy-5.




Figure S2 The uptake of the NPs by M1Φ decreased in the presence of chlorpromazine (A–B) and cytochalasin D (C–D), indicating the uptake pathways related to clathrin-mediated endocytosis and micropinocytosis.




Figure S3 (A) Abdominal swelling was inhibited after M1 Φ treatment. (B) The peritoneal tumor size after treatment. (C) Tumor weight analysis after treatment. (D) The expression of the macrophage-related biomarkers in the tumor after treatment.




Figure S4 (A) Body weight changes. (B) Organ coefficient. (C). Pathological examination of the major organs (scale bar: 100 μ m).




Figure S5 The percentages of CD11c⁺ (A) or MHC-I⁺ (B) subsets of DCs in the tumors. The percentage of PD-L1⁺ MΦ (C) in tumor tissues.